Current status of radionuclide therapies in metastatic castration-resistant prostate cancer

The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains a huge challenge. Newer radionuclides, such as ²²³Ra, ¹⁷⁷Lu, ²²⁵Ac, etc., have shown efficacy in alleviating cancer-related pain and also in enhancing the prognosis of mCRPC patients. These novel radionuclides have emerged as important weapons in the treatment of mCRPC. This article reviews recent advances and key clinical trials in various radionuclides and their combinations in the application for treating mCRPC. Further directions of this new treatment strategy are also discussed in this review.